TEPEZZA IS INDICATED FOR THE TREATMENT OF THYROID EYE DISEASE (TED)
Proptosis reduction at Week 6 in
some patients continued through
Week 24*
Significant proptosis reduction in
randomized, double-masked,
placebo-controlled study†
TEPEZZA has been shown to be
effective in patients with a wide
range of clinical manifestations
Complete the PDF of the Patient
Enrollment Form to get your patient
started on TEPEZZA
Your patients may be eligible for the Amgen Commercial Co-pay Program‡
‡Subject to terms and conditions.Hi I'm Kimberly Cockerham and I'm a board certified ophthalmologist with sub-specialty training in orbit, plastics and neuroophthalmology.
Thyroid Eye Disease is a vision-threatening, chronic disorder. Patients usually present with bulging of their eyes, redness, swelling, and complete disfigurement. They don't feel good about how they look, they're in pain. They're angry, and frustrated.
When somebody comes in and they're experiencing these symptoms, what are they really going through? It is very likely that a patient has seen multiple other practitioners with no results. I've had numerous patients who are approaching a decade or more of failed therapeutics.
Now things are different. Prior to January of 2020 when TEPEZZA was FDA approved as the first targeted treatment for Thyroid Eye Disease, there weren't a lot of options. Now I have TEPEZZA. It acts pretty quickly, and TEPEZZA makes the muscles behind the eye smaller. The redness and swelling go away. So, it's given me another tool in my tool chest.
Because of TEPEZZA, my conversations with my patients have changed for the better. I have a patient, and she gave me a picture of herself just before the Thyroid Eye Disease started. And then she showed me a picture of her in the midst of the disease, all alone, sad, frustrated. And then she sent me a picture just a couple of weeks after her last infusion, and her proptosis had improved, her eyes weren't bulging, she was really looking much more like herself again, and there she was, with her son, her grandchild and just beaming.
Each patient’s Thyroid Eye Disease journey is different, but it's really rewarding to be part of these patients' lives. Now, with TEPEZZA, I can help impact that journey.
The assistance offered under this co-pay program is subject to additional terms and conditions, including but not limited to the following:
Terms and Conditions: Offer cannot be combined with any other rebate or coupon, free trial, or similar offer for the specified prescription. Not valid for prescriptions reimbursed in whole or in part by any government-funded program including but not limited to Medicare, Medicare Part D, Medicaid, Medigap, VA, CHAMPUS, DOD, TRICARE, or any state, patient foundation, or other pharmaceutical program. Offer good only in the United States at participating specialty pharmacies or sites of care. Offer not valid were otherwise prohibited by law, for example by applicable state law prohibiting co-pay cards. Amgen reserves the right to rescind, revoke, or amend offer without notice. The selling, purchasing, trading, or counterfeiting of any co-pay card or benefits is prohibited by law. This co-pay program is not insurance and is not intended to substitute for insurance. Age for eligibility is dependent on product indication.
Participating Pharmacies or Healthcare Providers: By using this co-pay program, you acknowledge and confirm that the prescription will not be reimbursed in whole or in part by any government-funded program (such as, without limitation, Medicare, Medicaid, VA, DOD, TRICARE) and the patient and prescription meet the eligibility criteria set forth in the terms and conditions. You are responsible for reporting the receipt of the co-pay program benefits as required by an insurer, payor, or applicable law or regulation.
Patients: By enrolling in this co-pay program, you acknowledge and confirm that you and the prescription meet the eligibility requirements set forth in the terms and conditions, including that the prescription will not be reimbursed in whole or in part by any government-funded program (such as, without limitation, Medicare, Medicaid, VA, DOD, TRICARE). You may not seek any claims to government payors or other payors or insurers for this prescription. You may not seek reimbursement from any health savings, flexible savings, or other healthcare reimbursement account for any amounts received from the co-pay program. You are responsible for reporting the receipt of the co-pay program benefits as required by an insurer, payor, or applicable law or regulation.
TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.
Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.
Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.
Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA.
Hearing Impairment Including Hearing Loss: TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients’ hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.
The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, weight decreased, nail disorders, and menstrual disorders.
Please see Full Prescribing Information for more information.
TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.
Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4%
